TeklaLife Sciences (HQL)

Overall impact
D (33)

Commentary

TeklaLife Sciences is a below-average overall performer. With a 'D' rating of 33.3 for overall impact (bottom 25% of all companies), TeklaLife Sciences ranks 21st out of 27 industry peers, behind PhenixFIN, B&M European Value Retail, Kayne Anderson and 17 others, and ahead of Triplepoint Venture Growth, KPS Capital Partners, Royce Micro and 3 others. On top material causes for TeklaLife Sciences's industry (Financial Services), TeklaLife Sciences performs poorly in Affordable, Safe Housing (25.8 score), Quality Lifelong Education (21.9), Reduced Inequality (33.3) and 11 other causes where it received a 'D' or 'F' score. TeklaLife Sciences did not receive an 'A' rating on any cause.
Impact
Cause HQL
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

TeklaLife Sciences

Sector
Financials
Industry
Capital Markets
Sub-industry
Investment Banking & Brokerage
SASB industry
Asset Management & Custody Activities
Headquarters
Pa, United States
Share classes
HQL
Description
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Material causes
Ethos considers the following causes material for TeklaLife Sciences, based on its industry sub-industry Investment Banking & Brokerage. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.